[Form 4] Medtronic plc Insider Trading Activity

Rhea-AI Filing Summary

Form 4 shows President & CEO Christopher Hufnagel executed routine equity transactions in Wolverine World Wide (WWW) on 31 Jul 2025. He converted 13,154 restricted stock units (code M) into common shares at no cash cost, as RSUs convert 1-for-1. To satisfy tax-withholding obligations he disposed of 5,703 shares (code F) at $22.58 per share. Net of the withholding, Hufnagel added 7,451 shares to his direct holdings.

After the transactions, the CEO directly owns 231,558 common shares and retains 13,155 unvested RSUs from the July 2023 grant that vests in equal thirds through 2026. No derivative securities were sold for cash consideration. The filing indicates continued equity alignment by the CEO rather than an open-market sale, and does not alter control percentages or signal any change in corporate outlook.

Positive

• Net increase of 7,451 shares in CEO’s direct ownership, signalling ongoing alignment with shareholders.
• Majority (≈57%) of vested RSUs retained rather than sold, suggesting confidence in future performance.

Negative

• 5,703 shares disposed to cover withholding taxes, introducing minor selling pressure albeit administrative.

Insights

Securities Analyst

TL;DR: Routine RSU vesting; CEO retains majority of shares, modestly increasing direct stake.

The conversion of 13,154 RSUs and withholding of 5,703 shares for taxes is standard compensation practice. Net share addition of 7,451 reflects modest insider confidence, but dollar value (~$168k) is immaterial to WWW’s $1.8 bn market cap. No open-market buying or selling occurred, so minimal signalling value. I classify the filing as not impactful to valuation or liquidity.

Corporate Governance Expert

TL;DR: Filing shows compliance and continuing equity alignment; no governance red flags.

Hufnagel’s equity grant from 2023 continues to vest per schedule, and he retains over 87% of the released shares. The absence of discretionary sales limits perception of near-term pessimism. Adequate disclosure and power-of-attorney signature meet Section 16 requirements. From a governance standpoint, this is routine, low-risk activity with marginally positive alignment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Gregory L

(Last) (First) (Middle)

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MN 55432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Global Ops & Supply Chain

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/01/2025		M		11,328(1)	A	$0	83,071	D
Ordinary Shares	08/01/2025		F		4,458(2)	D	$89.34	78,613	D
Ordinary Shares	08/01/2025		F		2,656(3)	D	$89.34	75,957	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Units	(4)	08/01/2025		M			11,328	(5)	(5)	Performance Share Units	11,328	$0	0	D

Explanation of Responses:

1. Represents shares issued upon the settlement of performance-vesting restricted stock units granted on August 1, 2022 and earned dividend equivalents.

2. Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on August 1, 2025.

3. Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.

4. Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

5. The performance share units vested on August 1, 2025.

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Wolverine World Wide (WWW) shares did the CEO acquire on 31 July 2025?

He acquired 13,154 shares through RSU conversion and retained a net 7,451 shares after tax withholding.

At what price were shares withheld for taxes in the Form 4?

Shares were withheld at $22.58 per share under transaction code F.

What is Christopher Hufnagel’s total direct ownership after the transaction?

Following the filing, the CEO directly owns 231,558 common shares of WWW.

How many unvested RSUs does the CEO still hold?

He retains 13,155 restricted stock units that will vest in future periods.

Is the Form 4 transaction considered an open-market sale?

No. The sale (code F) was solely to cover taxes; no discretionary open-market sale occurred.